Use of the Guardian Connect glycemic monitoring system in patients after total duodenopancreatectomy in the early postoperative period on intravenous insulin therapy

BACKGROUND: Among different subtypes of pancreatogenic diabetes mellitus the biggest difficulties of glycemic control arise in patients after total duodenopancreatectomy (TDPE), first of all due to the presence of absolute insulin insufficiency.

AIM: Estimating safety and cost-effectiveness Guardian Connect CGM system in early postoperative period in hospitalized patients after TDPE on continuous intravenous insulin therapy (CIVIT).

MATERIALS AND METHODS: Glucose measurement results of 26 patients in early postoperative period after TDPE were analyzed. In 12 of them, we used Guardian Connect CGM system. In this group 43 cycles (1 cycle — 6 days, 258 days total) of CGM and 971 glucometer measurements used for CGM calibration were analyzed; in other 14 patients in whom only glucometer was used we analyzed 2496 glycemic values.

Cost-effectiveness was calculated over 6 days for CGM and only glucometer use (including cost of CGM, glucometers, disposable materials, clinic wage-costs to medical staff for time required for glucose control).

RESULTS: Glucose levels of group #1 were in the target range 5.6 to 10.0 mmol/L (66.7 vs 61.2%, p=0.003) and the range 4.3–11.6 mmol/L (85.2% vs 82.2%, p=0.038) more than in comparison with group #2.

The frequency of hypoglycemic episodes (<3.9 mmol/L) was statistically significantly lower in the CGM group (6 vs 54, p<0.001, RO 8.463 [3.579; 20.015], RR 1.746 [1.551; 1.966]).

Cost analysis of glucose control using Guardian Connect CGM system for one cycle (6 days) and cost of glucose control using glucose meter for the same period showed that using Guardian Connect CGM system in patients after TDPE on intravenous insulin therapy reduced clinic costs by 21.7% in ICU and by 25.7% in the hospital department.

CONCLUSION: Guardian Connect CGM have demonstrated its safety and cost-effectiveness during glucose control in patients in early postoperative period after TDPE on CIVIT.

1. Тарасова Ж.С., Бордин Д.С., Килейников Д.В., Кучерявый Ю.А. Панкреатогенный сахарный диабет: взгляд эндокринолога и гастроэнтеролога // Эффективная фармакотерапия. — 2020. — Т. 16. — №15. — С. 92–100. https://doi.org/10.33978/2307-3586-2020-16-15-92-100

2. Zakharova OP, Karmazanovsky GG, Egorov VI. Pancreatic adenocarcinoma: Outstanding problems. World J Gastrointest Surg. 2012; 4(5): 104-113 URL: http://www. wjgnet.com/1948-9366/full/v4/i5/104.htm https://dx.doi.org/10.4240/wjgs.v4.i5.104

3. Falconi M. Total pancreatectomy: how, when and why? Updates Surg. 2021. Aug;73(4):1203-1204. https://doi.org/10.1007/s13304-021-01134-z

4. Duron F, Duron JJ. Pancréatectomie et diabète [Pancreatectomy and diabetes]. Ann Chir. 1999;53(5):406-11. French

5. Scavini M, Dugnani E, Pasquale V, et al. Diabetes after pancreatic surgery: novel issues. Curr Diab Rep. 2015 Apr;15(4):16. https://doi.org/10.1007/s11892-015-0589-2

6. Jamil LH, Chindris AM, Gill KR, et al. Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: an exploratory study. HPB Surg. 2012;2012:381328. https://doi.org/10.1155/2012/381328

7. Furbetta N, Comandatore A, Gianardi D, et al. Perioperative Nutritional Aspects in Total Pancreatectomy: A Comprehensive Review of the Literature. Nutrients. 2021 May 22;13(6):1765. https://doi.org/10.3390/nu13061765

8. Scholten L, Stoop TF, Del Chiaro M, et al. Systematic review of functional outcome and quality of life after total pancreatectomy. Br J Surg. 2019 Dec;106(13):1735-1746. https://doi.org/10.1002/bjs.11296

9. Khatkov IE, Maev IV, Abdulkhakov SR, et al. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. Ter Arkh. 2018;90(8):13-26. https://doi.org/10.26442/terarkh201890813-26

10. Gosmanov AR, Umpierrez GE. Management of hyperglycemia during enteral and parenteral nutrition therapy. Curr Diab Rep. 2013 Feb;13(1):155-62. https://doi.org/10.1007/s11892-012-0335-y

11. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. — 10-й выпуск (доп.). — М.; 2021. https://doi.org/10.14341/DM12802

12. Nuha A. Elsayed, Grazia Aleppo, Vanita R. Aroda, et. all; on behalf of the american diabetes association, 16. diabetes care in the hospital: standards of care in diabetes—2023. Diabetes Care. 1 january 2023; 46 (supplement_1): s267–s278. https://doi.org/10.2337/dc23-s016

13. Elias K. Spanakis, Agustina Urrutia, Rodolfo J. Galindo, et al. Continuous Glucose Monitoring — Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial. Diabetes Care 1 October 2022; 45 (10): 2369–2375. https://doi.org/10.2337/dc22-0716

14. Buschur EO, Faulds E & Dungan K. CGM in the Hospital: Is It Ready for Prime Time? Curr Diab Rep. 22, 451–460 (2022). https://doi.org/10.1007/s11892-022-01484-x